Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages

  Zucca, E ^a   Copie Bergman, C ^b   Ricardi, U ^c   Thieblemont, C ^d   Raderer, M ^e   Ladetto, M ^f  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY OF TURIN   (Italy)

^d SAINT LOUIS HOSPITAL   (France)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; FLUDARABINE; METRONIDAZOLE; PROTON PUMP INHIBITOR; RITUXIMAB;

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; DRUG TOLERANCE; ERADICATION THERAPY; FOLLOW UP; HELICOBACTER INFECTION; HUMAN; IMMUNOTHERAPY; JAPANESE; MARGINAL ZONE LYMPHOMA; MYELODYSPLASTIC SYNDROME; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH LYMPHOMA; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; EUROPE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOID TISSUE; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 84885359565     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt343     Document Type: Article

References (24)

1. Bertoni F, Coiffier B, Salles G et al. MALT Lymphomas: pathogenesis can drive treatment. Oncology 2011; 25: 1134-1142, 1147.
2. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005; 23: 6415-6420.
3. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematol Am Soc Hematol Educ Program 2005; 307-313.
4. Isaacson PG, Chott A, Nakamura S et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In Swerdlow SH, Campo E, Harris NL et al. (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press 2008; 214-217
5. Dreyling M, Thieblemont C, Gallamini A et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857-877.
6. Ruskone-Fourmestraux A, Fischbach W, Aleman BM et al. EGILS Consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-758.
7. Rohatiner A, d'Amore F, Coiffier B et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397-400.
8. Ruskone-Fourmestraux A, Dragosics B, Morgner A et al. Paris staging system for primary gastrointestinal lymphomas. Gut 2003; 52: 912-913.
9. Raderer M, Wöhrer S, Streubel B et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24: 3136-3141.
10. Fuccio L, Laterza L, Zagari RM et al. Treatment of Helicobacter pylori infection. BMJ 2008; 337: a1454.
11. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non- Hodgkin's lymphomas. Hematol Oncol 2005; 23: 10-17.
12. Wirth A, Gospodarowicz M, Aleman BM et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group Study. Ann Oncol 2013; 24: 1344-1351.
13. Koch P, Probst A, Berdel WE et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT 'NHL 02/96). J Clin Oncol 2005; 23: 7050-7059.
14. Martinelli G, Laszlo D, Ferreri AJ et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti- Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983.
15. Zucca E, Conconi A, Laszlo D et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginalzone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013; 31: 565-572.
16. Nakamura S, Sugiyama T, Matsumoto T et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-513.
17. Zullo A, Hassan C, Cristofari F et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-110.
18. Saito Y, Suzuki H, Tsugawa H et al. Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS One 2012; 7: e47396.
19. Copie-Bergman C, Wotherspoon AC, Capella C et al. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol 2013; 160: 47-52.
20. Stathis A, Chini C, Bertoni F et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009; 20: 1086-1093.
21. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007; 56: 1685-1687.
22. Wündisch T, Thiede C, Morgner A et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018-8024.
23. Capelle LG, de Vries AC, Looman CW et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44: 2470-2476.
24. Wündisch T, Dieckhoff P, Greene B et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology 2012; 143: 936-942.